Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor α agents: An open-label observational study [8]

Annals of the Rheumatic Diseases

Volumn 65, Issue 9, 2006, Pages 1255-1257

  Brulhart, L ^a   Ciurea, A ^b   Finckh, A ^a   Notter, A ^b   Waldburger, J M ^a   Kyburz, D ^b   Gabay, C ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AUROTHIOMALATE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747798691     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.051169     Document Type: Letter

References (11)

1. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-11.
2. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62(Suppl 2):ii55-9.
3. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
5. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
6. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
7. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-5.
8. Fleischmann RM, Pavelka K, Baldassare AR, Martin-Mola E, Chatpar PC, Nash PT, et al. Preliminary efficacy results of rituximab retreatment in patients with active rheumatoid arthritis. Arthritis Rheum 2005;52:S131.
9. Cohen SB, Greenwald M, Dougados MR, Emery P, Furie R, Shaw TM, et al. Efficacy and safety of rituximab in active RA patients who experienced an inadequate response to one or more anti-TNF alpha therapies (REFLEX study). Arthritis Rheum 2005;52:S677.
10. Edwards JC, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology (Oxford) 2005;44:151-6.
11. Jimenez-Boj E, Redlich K, Turk B, Hanslik-Schnabel B, Wanivenhaus A, Chott A, et al. Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 2005;175:2579-88.